Photios Michael Frank Vassilyadi, MD
Internal Medicine · Lawrenceburg, TNNPI 1821519257
Payments from drug & device makers
Across 180 payments — averaging $20.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$590
- Novo Nordisk$467
- Esperion Therapeutics, Inc.$268
- Pfizer$202
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$188
- plus $892 from 18 others
What the payments were for
- Food & beverage$3,70898%
- Education$652%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 24 | $1,165 |
| AbbVie | 42 | $590 |
| Novo Nordisk | 27 | $467 |
| Esperion Therapeutics, Inc. | 16 | $268 |
| Pfizer | 12 | $202 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $188 |
| GSK | 11 | $184 |
| Xeris Pharmaceuticals, Inc. | 4 | $80 |
| Abbott | 3 | $65 |
| Lilly USA, LLC | 4 | $65 |
| Amgen | 4 | $64 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $59 |
| Novartis | 4 | $55 |
| Johnson & Johnson | 3 | $53 |
| Bayer | 2 | $48 |
| Dexcom, Inc. | 2 | $42 |
| Boehringer Ingelheim | 3 | $41 |
| Medtronic(2 entities) | 2 | $33 |
| Astellas Pharma US Inc | 1 | $23 |
| Exact Sciences | 1 | $20 |
| Recor Medical Inc | 1 | $16 |
| Boston Scientific | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Insulet Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,773 in reported general payments places this provider in the 80th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 304 | $222,020 |
| MounjaroTirzepatide | 187 | $206,761 |
| OzempicSemaglutide | 141 | $197,349 |
| FarxigaDapagliflozin Propanediol | 168 | $145,423 |
| JardianceEmpagliflozin | 67 | $70,074 |
| XifaxanRifaximin | 21 | $69,015 |
| XareltoRivaroxaban | 75 | $61,817 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 47 | $50,352 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $49,981 |
| TrulicityDulaglutide | 42 | $48,856 |
| Xigduo XrDapaglifloz Propaned/Metformin | 24 | $35,982 |
| NuplazidPimavanserin Tartrate | 13 | $35,595 |
| LinzessLinaclotide | 53 | $35,367 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 36 | $34,485 |
| UbrelvyUbrogepant | 21 | $28,349 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $65 | $255,617229 claims |
| PfizerEliquis, Nurtec Odt | $202 | $236,425319 claims |
| Novo NordiskOzempic | $467 | $197,349141 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,165 | $195,775215 claims |
| AbbVieLinzess, Ubrelvy, Vraylar | $590 | $77,06887 claims |
| Johnson & JohnsonXarelto, Risperdal Consta | $53 | $72,99692 claims |
| Boehringer IngelheimJardiance | $41 | $70,07467 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $59 | $69,01521 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $184 | $62,20570 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $268 | $27,14936 claims |
| NovartisEntresto | $55 | $25,96931 claims |
| Astellas Pharma US IncMyrbetriq | $23 | $14,52118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Lawrenceburg
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
- John KirbyJefferson City$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.